Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) has achieved Great Place to Work certification, based on feedback from 5,679 U.S. employees. An impressive 86% reported Agilent as a great workplace, significantly higher than the 59% benchmark for typical U.S. companies. The recognition underscores Agilent's commitment to fairness, equity, and integrity, reflected in high scores for treatment of employees across various demographics. Additionally, Agilent is recognized globally, having won similar awards in China, Germany, India, and Spain.
Agilent Technologies (NYSE: A) has established in-country manufacturing for its SureSelect portfolio at its Hangzhou, China facility. This move aims to enhance delivery turnaround times for next-generation sequencing assays, allowing faster development and optimization of custom panels. The new manufacturing site will maintain the same high-quality standards as U.S. counterparts, enabling quicker customer access to assay technology. Agilent's investment reflects its commitment to growth opportunities in the China market and reinforces its genomics capabilities.
Agilent Technologies (NYSE: A) announced the 2021 Early Career Professor Award recipient, Dr. Jason H. Yang, from Rutgers New Jersey Medical School. This award focuses on innovative solutions for managing immunological responses to diseases. Dr. Yang's research combines high-throughput experimentation with machine learning to develop engineered macrophages as therapies for infections, autoimmunity, and cancer. The award supports his cutting-edge research and strengthens Agilent's commitment to advancing scientific innovation.
Agilent Technologies Inc. (NYSE: A) announced a study published in the journal Lung Cancer, highlighting the effectiveness of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for detecting ALK fusions in lung cancer patients. Conducted in collaboration with Resolution Bioscience and Memorial Sloan Kettering Cancer Center, the study emphasizes the non-invasive nature and clinical utility of this method. Findings suggest that ctDNA testing can monitor resistance mechanisms in patients undergoing targeted therapy, supporting precision oncology.
Summary not available.
Agilent Technologies Inc. (NYSE: A) will announce its third-quarter fiscal year 2021 financial results on Tuesday, August 17, after market close. A live webcast for the investor conference call will occur the same day at 1:30 p.m. Pacific time, accessible via the Investor Relations section of Agilent's website. The company reported revenues of $5.34 billion in fiscal year 2020 and employs 16,400 individuals globally. The webcast will be available for 90 days following the event.
Agilent Technologies (NYSE: A) has expanded the labeling of its PD-L1 IHC 22C3 pharmDx assay for use in patients with non-small cell lung cancer (NSCLC) in the European Union. The assay helps identify NSCLC patients with Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). Lung cancer is the leading cause of cancer death, with NSCLC accounting for about 85% of cases. This initiative underscores Agilent's commitment to developing diagnostics for targeted cancer therapy.
Agilent Technologies Inc. (NYSE: A) has launched a new eMethod for PFAS Analysis in Water using liquid chromatography and mass spectrometry. This solution enables rapid testing for over 100 PFAS compounds in drinking and surface water, significantly reducing analysis time from weeks to hours. The method aligns with evolving global regulations, helping environmental customers update their testing protocols. The comprehensive analytical workflow includes sample preparation, acquisition, and quantitation methods, ensuring compliance with current and future regulations.
MOBILion Systems Inc. has successfully completed a $60 million Series C financing round, led by D1 Capital Partners. This funding will support the commercialization of its first product, MOBIE®, a High-Resolution Ion Mobility tool designed for biopharmaceutical drug development. The technology aims to enhance the speed and accuracy of protein characterization, vital for quality monitoring in drug development. The company plans to expand its market presence, particularly in emerging fields like cell and gene therapy.
Agilent Technologies Inc. (NYSE: A) announced a significant study in partnership with Resolution Bioscience and Dana-Farber Cancer Institute, published in the New England Journal of Medicine. The study explores the clinical utility of liquid biopsy techniques for detecting resistance to KRAS G12C inhibitors like adagrasib in cancer treatment. It reveals diverse mutations leading to resistance, emphasizing the need for new therapeutic strategies. Notably, cfDNA analysis enabled more effective genotyping, improving patient outcomes in targeted therapies.